logo-loader
viewCytoDyn Inc.

CytoDyn takes major step forward filing trial protocol for HIV Monotherapy

CytoDyn (OTCQB:CYDY) CEO Nader Pourhassan joined Steve Darling from Proactive Investors Vancouver on Skype to bring news the company has filed to the FDA,  the pivotal trial protocol for leronlimab as a monotherapy for HIV patients. 

Pourhassan also shared details about the work involved to get to this point and what the next stage is.

Quick facts: CytoDyn Inc.

Price: 2.9399 USD

OTCMKTS:CYDY
Market: OTCQB
Market Cap: $1.26 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of CytoDyn Inc. named herein, including the promotion by the Company of CytoDyn Inc. in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

CytoDyn sees impressive results with Leronlimab on very ill COVID-19 patients

CytoDyn (OTCQB: CYDY) CEO Dr Nader Pourhassan and IncellDX CEO Dr Bruce Patterson joined Steve Darling from Proactive Vancouver with news that the three-day effect of leronlimab in eight severely ill COVID-19 patients demonstrated a significant improvement in several important immunologic...

23 hours, 54 minutes ago

2 min read